Professor Steve Wilton, along with colleague Professor Sue Fletcher, were early pioneers in the use of antisense oligomers to treat Duchenne muscular dystrophy (DMD). Three exon-skipping compounds from his group have now been approved by the US FDA to restore functional dystrophin expression in the most common mutations causing DMD. His research team is currently exploring treatments for scores of diseases, aiming to develop new therapeutics for many inherited and/or acquired conditions. This work has been recognised with several awards, including a Eureka prize, over the last decade. He was made an Officer of the Order of Australia in 2021.
Menu